When it comes to liver oncology, silencing of ANXA2 arrested the cell cycle in vitro, inhibited tumor growth in vivo [94], and suppressed the invasion, migration, and tumorigenic potential of HCC cells [93]. Here, ANXA2 is linked to hepatocellular carcinoma.